MBB 446 Lecture 5 Flashcards

1
Q

What was the 1970’s theory regarding viruses and cancer? Problem?

A
  • theory that DNA and RNA tumor viruses could infect tissue, cause transformation of infected cells, and lead to cancer (based on observations in rodent and chicken cells)
  • most types of human cancer did not spread like infectious disease; “clusters” (mini-­epidemics) of cancer cases were hard to find; attempts to isolate viruses from human tumors were unsuccessful
  • Exceptions: cervical carcinomas and hepatomas (liver cancer); linked to specific viral causative agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How did most of the endogenous retroviral genomes present in the human genome come about?

A

result of germ-­line infections that occurred 5 million years ago;; proviruses sequences mutated and could no longer encode infectious retroviral particles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

% of human genome that derives from endogenous retroviral genomes?

A

Up to 8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Retroviruses can lead to cancer by deregulating genes at their sites of ______ (insertional mutagenesis) in animal models-­-­-­-­-­-­but no evidence in humans

A

integration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

_______ have comparable incidence rates

_______ highly variable incidence rates

A

Pediatric tumors have comparable incidence rates

Skin cancer – highly variable incidence rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define incidence

A

of new cases of disease; can be reported as a risk or as an incidence rate; frequency with which a disease occurs or is diagnosed in a population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define prevalence

A

of existing cases of a disease, at a particular point in time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can incidence be low but prevalence high? Giveexample

A

In slow progressing diseases e.g. incidence of pancreatic neuroendocrine tumors is low, but the prevalence is relatively high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What environment/lifestyle factors are etiologic for human cancers?

A
  1. Diet

2. Tobacco

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What were Katsusaburo Yamagiwa two main findings

A
  1. Directly implicated chemicals in cancer causation

2. Demonstrated that cancer can be induced in lab animals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Define carcinogen

A

Cancer-causing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Define mutagens

A

mutates DNA; many carcinogens can act as mutagens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define oncogenes

A
  • a gene capable of transforming a normal cell into a tumor cell
  • a gene that causes cells to grow in an uncontrolled manner
  • oncogenes are mutant forms of normal functional genes (called proto-oncogenes) that have a role in cell proliferation
  • proto-oncogenes have the intrinsic potential to induce cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How could the oncogenes be detected/found?

A

Transfection = gene transfer technique (to detect oncogene activity)

SHOWING mouse tumor transforming mouse cells

  1. Take chemically transformed mouse fibroblasts and isolate DNA
  2. Transfection using calcium phosphate co-precipitation procedure. Ca-P facilitates uptake of DNA into normal cells
  3. Inject into normal mouse fibroblasts
  4. Formation of a focus of morphologically transformed cells if transforming gene (oncogene) present in DNA
  5. Injection of morphologically transformed cells into mouse host
  6. Tumor formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Could the same group of cellular proto-­oncogenes be activated by retroviruses (e.g. by insertional mutagenesis) in one context and by non-­viral mutagens in other contexts? OR are there two distinct groups of cellular proto-­oncogenes?

A

N/A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the 6 main products of oncogenes? The one new “non-coding” class?

A
  1. Transcription factors
  2. Chromatin remodelling
  3. Growth factors
  4. Signal transducers
  5. Growth factor receptors
  6. Apoptosis regulators

And one “new” non-­coding class: miRNAs

17
Q

What are the 4 mechanisms of oncogene activation? How do they induce changes

A
  1. Gene amplification
  2. Chromosome rearrangement
  3. Mutation
  4. Post-transcriptional modification by miRNAs
  • Cause increase or deregulation of expression
  • Cause alteration of oncogene structure
18
Q

Example of each of the 4 mechanisms of oncogene activation?

A
  1. Gene amplification
    - Amplification of HER2 in human breast cancer
  2. Chromosome rearrangement
    - chromosomal translocation: formation of bcr-abl oncogene. “Philidelphia chromosome; reciprocal translocation of 9 and 22”
3. Mutation:
H-ras proto-oncogene
- Expression and structure appeared same
- DNA sequence analysis showed a single base substitution in which guanosine was substituted by thymidine; this single point mutation converted a normal gene into a potent oncogene (Glycine to Valine change)
- Ras Val12
  1. Post-transcriptional modification by miRNAs
19
Q

Describe the circos plot of genetic variation in liposarcoma

A

Inner-­most circle contains validated structural rearrangements of fusion genes with translocations indicated in purple, and intra-­ chromosomal rearrangements indicated in orange. The middle ring contains the aCGH plot with copy number loss indicated in green and copy number gain in red;; each orange ring corresponds to a log2 value of 1. The outer-­most ring indicates validated, damaging single nucleotide variants.

20
Q

How is abl-bcr fusion protein targeted by therapies?

A

fusion protein has tyrosine kinase activity that is targeted by therapies

21
Q

Different breakpoints in Bcr are associated with distinct ______

22
Q

How does translocation affect post-transcriptional regulation by miRNA? Example?

A

Translocation relieves miRNA-mediated suppression of translation. Translocation serves to liberate a proto-oncogene from neg regulation. E.g. HMGA2

23
Q

What is a OncomiR?

A
  • a microRNA associated with cancer
  • either fxn as oncogene or tumor suppressors
  • Involved in many cellular processes that are altered in cancer such as differentiation, proliferation and apoptosis
24
Q

Example of a oncomiRNA?

A

microRNA-21 (miR-21) is an miRNA overexpressed in many tumors

25
Q

How does H-Ras to Ras Val-12 mutation affect the fxn of Ras?

A

Oncogenic mutation inactivates the intrinsic GTPase activity of Ras
- Always in “on” state

26
Q

How can growth factor receptors, one of the main classes of oncogene products, act as oncoproteins?

A

Growth factor receptors can function as oncoproteins:

  • ligand-independent firing (mutation allows to dimerize in absence of ligand e.g. HER2 GFR)
  • autocrine signaling
27
Q

What is auto-stimulatory signaling loop

A

Auto-stimulatory signaling loop created when tumor cells acquire ability to express a growth factor not normally expressed; cognate receptor is already expressed by cells

28
Q

Describe the role of VEGF-VEGFR interaction in Angiogenesis

A

Several pathways are activated by interaction of vascular endothelial growth factor (VEGF) and VEGFRs. FAK = fatal adhesion kinase, Flk = fetal liver kinase, IP3 = inositol triphosphate, KDR = kinase-insert domain-containing receptor, MAPK mitogen-activated protein kinase, PI3K phosphoinositol 3-kinase, PKB = protein kinase B, and PLC = phosholipase C

29
Q

What are anticancer drugs/therapeutics that are monoclonal Abs? What is their target and disease?

Small molecules? What are their target and disease?

A

Monoclonal Ab
1. Bevacizumab (Avastin)
Target: VEGF
Disease: Colorectal cancer, non-small cell lung cancer

Small molecules
Sunitinib (Pfizer)
Target: VEGF
Disease: GI stromal tumors

30
Q

What suffix is used for monoclonal Ab therapeutics?

31
Q

What suffix is used for polyclonal Ab therapeutics?

32
Q

What suffix is used for protein tyrosine kinase inhibitor (small molecule) therapeutics?